Baseline HPV Status and Risk for Future CIN2+ Cytology
Genotyping for HPV improves risk stratification when cytology is negative for intraepithelial lesions or malignancy (NILM)
Fröberg et al. (Cancer, 2019) sought to determine
Odds of developing high-grade CIN based on baseline HPV status
Impact of HPV genotyping based on the age (using the 30-year-old threshold)
Nested case-control study
Data extracted from the Swedish cervical screening program
96 CIN2+ cases
5 age-matched controls per case
Baseline samples tested with liquid-based cytology and also tested for HPV
14 HPV types studied, including 16 and 18
Age <30 years
HPV 16/18 was strongly associated with risk for subsequent CIN2+
16/18: Odds ratio (OR) 9.44 (95% CI, 3.37-26.4)
Other HPV types were not found to be significantly associated with future CIN2+
Age ≥30 years
Both 16/18 and other HPV types were strongly associated with risk for subsequent CIN2+
16/18: OR 8.16 (95% CI, 3.28-20.3)
Other types: OR 9.04 (95% CI, 3.42-23.9)
Baseline positive HPV status in women NILM is highly associated with future high risk CIN2+
HPV types 16 and 18 are strongly associated with risk in women <30, while both 16/18 and other HPV types have a significant risk impact on women ≥30 years of age
The authors call for more research and state
Accurate knowledge of HPV, CIN, and cervical cancer is indispensable, especially among women at increased cervical cancer risk and as cervical cancer screening becomes increasingly reliant on HPV testing.
Please log in to access ObGFirst and the 2T US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan